Serum GDF-15 Levels in Pediatric ADHD: Associations with Symptom Severity and Stimulant Exposure
Neuropsychiatric Disease and Treatment · 2026-07 · Volume 22 · 1-9
DOI: 10.2147/ndt.s622224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychiatric Disease and Treatment, 2026-07. Verfasst von Selçuk Özkan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Türkiye. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry, Faculty of Medicine, Kütahya Health Sciences University, Kütahya, Türkiye.
- Department of Biochemistry, Kütahya Health Sciences University, Kütahya, Türkiye.
ORCID-Profile: Selçuk Özkan
Zitieren
APA
Özkan, S., Can, F., & Höbel, A. (2026). Serum GDF-15 Levels in Pediatric ADHD: Associations with Symptom Severity and Stimulant Exposure. Neuropsychiatric Disease and Treatment, Volume 22, 1-9. https://doi.org/10.2147/ndt.s622224
Vancouver
Özkan S, Can F, Höbel A. Serum GDF-15 Levels in Pediatric ADHD: Associations with Symptom Severity and Stimulant Exposure. Neuropsychiatric Disease and Treatment. 2026;Volume 22:1-9. doi:10.2147/ndt.s622224
BibTeX
@article{zkan2026,
author = {Özkan, Selçuk and Can, Fatmagül and Höbel, Asiye},
title = {Serum GDF-15 Levels in Pediatric ADHD: Associations with Symptom Severity and Stimulant Exposure},
journal = {Neuropsychiatric Disease and Treatment},
year = {2026},
volume = {Volume 22},
pages = {1--9},
doi = {10.2147/ndt.s622224}
}
EUVIMED